NormOxys, Inc. Initiates Phase 1 Clinical Trial of Allosteric Effector of Hemoglobin, OXY111A

WELLESLEY, Mass.--(BUSINESS WIRE)--NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications. The Phase 1 trial will evaluate OXY111A in healthy volunteers at escalating dose levels.

Back to news